The best basic science paper in multiple sclerosis in 2014: Citicoline,remyelination and neuroprotection: Commentary

Abstract

Keywords

Atrophy MRI citicoline Multiple sclerosis remyelination neuroprotection

Get full access to this article

View all access options for this article.

References

Geurts

Calabrese

Fisher

. Measurement and clinical effect of gray matter pathology in multiple sclerosis. Lancet Neurol 2012; 11: 1082–1092.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Skripuletz

Manzel

Gropengießer

. Pivotal role of choline metabolites in remyelination. Brain 2014 Dec. 17. pii: awu358.

Knippenberg

Skripuletz

Rath

. CDP-choline is not protective in the SOD1-G93A mouse model of ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 284–290.

Overgaard

. The effects of citicoline on acute ischemic stroke: A review. Stroke Cerebrovasc Dis 2014; 23: 1764–1769.

Qian

Zhao

. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem Res 2014; 39: 1206–1218.

Grieb

. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs 2014; 28: 185–193.

Chataway

Schuerer

Alsanousi

. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213–2221.

Anderson

Bartlett

Fox

. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J Neurol 2007; 254: 1588–1594.

10.

Nakamura

Guizard

Fonov

. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin 2013; 4: 10–17.

11.

Salzer

Svenningsson

Sundström

. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287–292.

12.

Trentini

Comabella

Tintoré

. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261: 2338–2343.